Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 112,640

Document Document Title
WO/2016/136907A1
Provided is a highly safe apoptosis inhibitor having an excellent effect in inhibiting apoptosis. An apoptosis inhibitor containing as an active ingredient a compound shown by formula (1). (In the formula, R1 and R2 each independently ar...  
WO/2016/138135A1
This invention provides a method of treating a subject suffering from a neurodegenerative disease or neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a modulator of the Sigma-1 rece...  
WO/2016/135048A1
The present invention relates to novel pyridine derivatives of formula (I) as A2B adenosine receptor antagonists and ligands of MT3 melatonin receptor, to processes for their preparation, to pharmaceutical compositions comprising said co...  
WO/2016/136933A1
A pharmaceutical composition for treating IL-6-related diseases having as an active ingredient an IL-6 inhibitor, wherein the pharmaceutical composition is administered as usual after a short-interval dosing period where the same dose as...  
WO/2016/135644A1
The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.  
WO/2016/135199A1
The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation com...  
WO/2016/137788A1
The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.  
WO/2016/137811A1
Monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including Alzheimer-s disease, Progressive Supranuclear P...  
WO/2016/138270A2
Composition and methods for treating brain "plaques" and "tangles" in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract and an o...  
WO/2016/136727A1
A drug for preventing and/or treating dementia comprising as an active ingredient a compound represented by formula (I) that has a xanthine oxidase inhibitory effect.  
WO/2016/134563A1
Disclosed is a use of albiflorin or a pharmaceutically acceptable salt for the prevention and/or treatment of irritable bowel syndrome. The experimental results demonstrate that the prevention, remission and/or treatment of irritable bow...  
WO/2016/138130A1
This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive fu...  
WO/2016/134091A1
The invention is directed to a method for improving learning and/or memory (e.g., auditory, visual, somatosensory or motor) in adults and children of an age which is beyond the early critical period for learning, said method comprising i...  
WO/2016/134246A2
The present invention relates to the field of protein conformational diseases. More specifically, the present invention provides compositions and methods for treating protein conformational diseases including amyotrophic lateral sclerosi...  
WO/2016/131776A1
The invention provides compounds for use in the treatment of a disease or condition selected from brain disorders and triple-negative breast cancer, the compounds being of the formula (1) or a salt or tautomer thereof; wherein: X1 is N o...  
WO/2016/131098A1
ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in ...  
WO/2016/132217A1
The present invention provides a method of improving GABAB receptor agonist therapy. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor ag...  
WO/2016/132220A1
The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage for...  
WO/2016/132218A1
The present invention provides a simple and improved method of administering a controlled release dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also pro...  
WO/2016/133160A1
The purpose of the present invention is to provide a novel low molecular weight compound that exhibits orexin receptor agonist activity and is expected to be useful as an excellent preventative or therapeutic agent for narcolepsy or the ...  
WO/2016/132233A1
The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage f...  
WO/2016/131947A1
The present invention relates and the combination of lacosamide and brivaracetam for the preparation of a fixed dose combination that is useful in the treatment of epilepsy, epileptogenesis, seizure disorders and convulsions.  
WO/2016/131640A1
The present invention provides a medium chain fatty acid (MCFA) for use in treating and/or preventing anxiety.  
WO/2016/132343A1
The present invention describes a process for the synthesis of 3-(2-cyanophenyl)-5-(2- pyridyl)-1-phenyl-1,2-dihydro-pyridin-2-one (Perampanel) represented by the structure of formula (1), and salts thereof, especially salts with pharmac...  
WO/2016/133788A1
Provided are methods and compositions for preventing, reducing, mitigating and treating pain, particularly neuropathic pain by the combined administration of an agent that increases EETs and an agent that reduces/inhibits endoplasmic ret...  
WO/2016/134049A1
Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt the...  
WO/2016/134032A1
Provided are methods for treating or preventing brain edema in a subject by administering an inhibitor of SLC26A11 to the subject. Also included are methods for preventing cell death, cell swelling, or elevated internal concentration of ...  
WO/2016/134292A1
Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.  
WO/2016/133446A1
The compound N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl )-1,3,5-triazine- 2,4-diamineor a pharmaceutically acceptable salt of said compound. The compound is useful the treatment of a condition or disorder associated wit...  
WO/2016/134042A2
In certain embodiments compounds (e.g., triazolopyrimidine(s) and/or triazolopyridine(s)) are provided that are effective to lower p-tau and/or to prevent or reduce elevation of p-tau, particularly in response to stress (e.g., elevated c...  
WO/2016/128132A1
Novel 2-oxoesters are described. Also described are uses thereof, such as for inhibition of phospholipase A2 activity. Therapeutic uses thereof are also described, such as for the treatment of neural conditions and/or inflammatory condit...  
WO/2016/130589A3
Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e....  
WO/2016/127962A1
The invention relates to a novel, physically stable, solid form of suvorexant, chemically [(7R)- 4-(5-chloro- 1,3 -benzoxazol-2-yl)-7-methyl- 1,4-diazepan- 1 -yl] [5-methyl- 2-(2H-l,2;3-triazol-2-yl)phenyl]methanone with sulphuric acid, ...  
WO/2016/127831A1
The present invention provides an application of chlorogenic acid in preparing medicines for treating the Parkinson's disease.  
WO/2016/129627A1
The present invention provides a screening method for pain-relieving substances, said method characterized by the use of FLRT3 to select substances that inhibit the expression of FLRT3, or substances that inhibit transport of FLRT3 to th...  
WO/2016/130901A2
Compounds and methods for treating diseases or conditions affected by the activity or expression of genes/proteins related to human GH, GHR, STAT5, SOCS, IGF-1, insulin are provided. Monoclonal antibodies for treating diseases or conditi...  
WO/2016/130589A2
Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e....  
WO/2016/130920A2
Compounds having the formula (I), (II), (III) are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.  
WO/2016/128771A1
The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein: Z is OR16 or NR17R18; R16 is H or alkyl; R17 is H or alkyl; R18 is alkyl or cycloalkyl, each of which i...  
WO/2016/130796A1
Disclosed are compounds of Formula (I): (Formula (I)) and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These co...  
WO/2016/128990A1
The present invention relates to compounds of formula (I), including their stereoisomers and pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising su...  
WO/2016/127399A1
The present invention provides use of chlorogenic acid in preparing a drug for treating amyotrophic lateral sclerosis. The chlorogenic acid is beneficial to alleviating disease symptoms of amyotrophic lateral sclerosis (ALS), beneficial ...  
WO/2016/130460A2
Compounds, compositions, kits and methods for treating conditions related to Retinal degenerations, and related diseases, including retinitis pigmentosa and atrophic age-related macular degeneration, are disclosed.  
WO/2016/128772A1
The present invention relates to BKCa activators for use in the treatment of a muscular disorder, or for controlling spasticity or tremors, for example, spasticity in MS.  
WO/2016/129583A1
The invention provides a lactate dehydrogenase inhibitor that makes it possible to suppress refractory epilepsy in which conventional antiepileptic drugs are ineffective, and an antiepileptic drug containing said inhibitor. The lactate d...  
WO/2016/127221A1
The present invention relates to compositions, methods and kits for the treatment of pain. In particular, the compositions, methods and kits are for the treatment of pain associated with headache or migraine or period pain. In particular...  
WO/2016/130501A1
The present invention provides aza-heteroaryl derivatives of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, W, R4, R5, and R6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamm...  
WO/2016/130460A9
Compounds, compositions, kits and methods for treating conditions related to Retinal degenerations, and related diseases, including retinitis pigmentosa and atrophic age-related macular degeneration, are disclosed.  
WO/2016/129140A1
An intraoral rapid disintegration tablet that comprises fine grains, said fine grains having, at the center, a drug substance-containing core containing butylscopolamine bromide and water-insoluble particles and being provided with an in...  
WO/2016/130790A1
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Ring B, A1, A2, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for...  

Matches 101 - 150 out of 112,640